JPH05184357A - Cell proliferation promoting agent and promoting method - Google Patents

Cell proliferation promoting agent and promoting method

Info

Publication number
JPH05184357A
JPH05184357A JP3300972A JP30097291A JPH05184357A JP H05184357 A JPH05184357 A JP H05184357A JP 3300972 A JP3300972 A JP 3300972A JP 30097291 A JP30097291 A JP 30097291A JP H05184357 A JPH05184357 A JP H05184357A
Authority
JP
Japan
Prior art keywords
promoting
opq
compound
formula
oxazopyrroloquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3300972A
Other languages
Japanese (ja)
Inventor
Osamu Suzuki
修 鈴木
Sadaji Uragami
貞治 浦上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Gas Chemical Co Inc
Original Assignee
Mitsubishi Gas Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Gas Chemical Co Inc filed Critical Mitsubishi Gas Chemical Co Inc
Priority to JP3300972A priority Critical patent/JPH05184357A/en
Publication of JPH05184357A publication Critical patent/JPH05184357A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PURPOSE:To provide the subject promoting agent composed of a oxazopyrroloquinoline compound or its ester and effective for promoting the proliferation of animal cell to increase the production efficiency of valuable products originated from the cell. CONSTITUTION:The objective promoting agent is composed of an oxazopyrroloquinoline compound and/or its ester expressed by formula [R is same as the R' of an alpha-amino acid of the formula R'-CH2(NH2)COOH; R<2> to R<3> are H, alkyl, alkenyl or benzyl]. The compound of formula is produced preferably by reacting a PQQ compound with various alpha-amino acids (e.g. glycine and valine) and methylamine, etc., in the presence of oxygen.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、オキサゾピロロキノリ
ン類および/またはそのエステル体から成る動物細胞の
増殖促進剤およびそれを用いる動物細胞の増殖促進方法
に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an animal cell growth promoter comprising oxazopyrroloquinolines and / or ester thereof and a method for promoting animal cell growth using the same.

【0002】[0002]

【従来の技術および発明が解決しようとする課題】動物
細胞を用いて種々の有用物質の生産が行われているが、
その際、培養に要する期間を短縮し、目的とする物質の
生産効率を高めることは経済性を考える際に最も重要な
ことである。従来、動物細胞の増殖を促進するために血
清培地が用いられてきた。しかしながら、血清培地は、
多成分の混合物であるために、培養後の目的物質の単離
精製操作が煩雑となり、また、有効成分が特定されてい
ないため、培養を安定的に行うことが困難であった。
BACKGROUND OF THE INVENTION Various useful substances have been produced using animal cells.
At that time, shortening the period required for culturing and increasing the production efficiency of the target substance are the most important factors when considering economical efficiency. Traditionally, serum media have been used to promote the growth of animal cells. However, the serum medium is
Since the mixture is a multi-component mixture, the procedure for isolating and purifying the target substance after culturing becomes complicated, and it is difficult to carry out the culturing stably because the active ingredient is not specified.

【0003】[0003]

【課題を解決するための手段】本発明者らは、前記した
理由により、動物細胞の増殖を促進する薬剤について鋭
意研究を進めたところ、オキサゾピロロキノリン類また
は、そのエステル体が、動物細胞の増殖を促進する効果
を示すことを見いだした。すなわち、本発明はオキサゾ
ピロロキノリン類またはそのエステル体から成る動物細
胞の増殖促進剤、および動物細胞を培養するに際し、培
地にオキサゾピロロキノリン類あるいはそのエステル体
を添加して該細胞の増殖を促進させ、該細胞由来の有用
産物の生産効率を高める方法である。
[Means for Solving the Problems] For the above-mentioned reasons, the inventors of the present invention have conducted extensive research into a drug that promotes the growth of animal cells, and found that oxazopyrroloquinolines or their esters are found in animal cells. It has been found that it has the effect of promoting the growth of. That is, the present invention relates to a growth promoter for animal cells, which comprises an oxazopyrroloquinoline or an ester thereof, and, when culturing an animal cell, adding oxazopyrroloquinoline or an ester thereof to a medium to grow the cells. And the production efficiency of useful products derived from the cells is enhanced.

【0004】オキサゾピロロキノリン類(以下OPQ類
と略す)とは、別名5位置換2,8,10−トリカルボ
キシ−1H−オキサゾ〔5,4−h〕−ピロロ〔2,3
−f〕キノリンおよびその塩であり、OPQ類およびそ
のエステル体の一般式は以下のごとく(式1)である。
Oxazopyrroloquinolines (hereinafter abbreviated as OPQs) are also known as 5-substituted 2,8,10-tricarboxy-1H-oxazo [5,4-h] -pyrrolo [2,3].
-F] quinoline and its salt, and OPQs and its ester form have the following general formulas (formula 1).

【0005】[0005]

【化3】 [Chemical 3]

【0006】本発明において使用されるオキサゾピロロ
キノリン類のRは、一般式R’−CH2 (NH2 )−C
OOHで示されるα−アミノ酸のR’とおなじであれば
よいが、好ましくは天然のα−アミノ酸のR’、更に好
ましくは天然の蛋白質を構成するα−アミノ酸のR’と
同一のものが好適である。
R of the oxazopyrroloquinoline used in the present invention is represented by the general formula R'-CH 2 (NH 2 ) -C.
It may be the same as the R'of the α-amino acid represented by OOH, but is preferably the same as the R'of the natural α-amino acid, and more preferably the same as the R'of the α-amino acid constituting the natural protein. Is.

【0007】本発明において使用されるOPQ類は、P
QQ類と各種のα−アミノ酸、メチルアミンなどとを酸
素存在下で反応させることにより、容易に製造すること
が可能である。
The OPQs used in the present invention are P
It can be easily produced by reacting QQs with various α-amino acids, methylamine and the like in the presence of oxygen.

【0008】本発明におけるOPQ類としては、PQQ
類とグリシン、スレオニン、トリプトファン、プロリ
ン、チロシン、セリンおよびモノメチルアミンのいずれ
か1種とから得られるOPQ(R=H)(特願平1−2
92459号)、PQQ類とセリンから得られるヒドロ
キシメチルOPQ(R=CH2 OH)(特願平1−25
8791号)、PQQ類とバリンから得られる1−メチ
ルエチルOPQ(R=CH(CH3 2 )(特願平1−
309479号)、PQQ類とイソロイシンから得られ
る1−メチルプロピルOPQ(R=CH(CH3 )CH
2 CH3 )(特願平1−309480号)、PQQ類と
ロイシンから得られる2-メチルプロピルOPQ(R=C
2 CH(CH3 2 )(特願平1−309481)、
PQQ類とアラニンから得られるメチルOPQ(R=C
3 )(特願平1−327347)、PQQ類とグルタ
ミン酸から得られる2−カルボキシエチルOPQ(R=
CH 2 CH2 COOH)(特願平1−327351
号)、PQQ類とグルタミンから得られる2−カルバモ
イルエチルOPQ(R=CH2 CH2 CONH2 )(特
願平1−327348号)、PQQ類とメチオニンから
得られる2−メチルチオエチルOPQ(R=CH2 CH
2 SCH3 )(特願平1−32749号)、PQQ類と
フェニルアラニンから得られるベンジルOPQ(特願平
1−327350号)、PQQ類とチロシンから得られ
る4−ヒドロキシフェニルメチルOPQ(特願平2−1
07354号)、PQQ類とアスパラギン酸から得られ
る1−カルボキシメチルOPQ(R=CH2 COO
H)、PQQとアスパラギンから得られる1−カルバモ
イルメチルOPQ(R=CH2 CONH2 )、PQQ類
とヒスチジンから得られる1−(4−イミダリール)メ
チルOPQ、PQQ類とリジンから得られる4−アミノ
ブチルOPQ(R=(CH2 4 NH2 )、PQQ類と
アルギニンから得られる3−グアニジノプロピルOP
Q、PQQ類とシステインから得られる1−メルカプト
メチルOPQ(R=CH2 SH)などがある。また、そ
れぞれのOPQ類の塩には、アルカリ金属塩、アルカリ
土類金属塩、アンモニウム塩および置換アンモニウム塩
などがあり、その代表例としては、ナトリウム塩、カリ
ウム塩、マグネシウム塩、カルシウム塩、アンモニウム
塩、トリメチルアンモニウム塩、トリエチルアンモニウ
ム塩、トリエタノールアンモニウム塩などがある。
As the OPQs in the present invention, PQQ
And glycine, threonine, tryptophan, prolyl
, Tyrosine, serine and monomethylamine
OPQ (R = H) obtained from 1 or 1 (Japanese Patent Application No. 1-2)
92459), a hydrolyzate obtained from PQQ and serine
Xymethyl OPQ (R = CH2OH) (Japanese Patent Application 1-25
8791), 1-Meth obtained from PQQs and valine
Luethyl OPQ (R = CH (CH3)2) (Patent application 1-
309479), obtained from PQQs and isoleucine
1-methylpropyl OPQ (R = CH (CH3) CH
2CH3) (Japanese Patent Application No. 1-309480), PQQ
2-Methylpropyl OPQ (R = C obtained from leucine
H2CH (CH3)2) (Japanese Patent Application No. 1-309481),
Methyl OPQ (R = C obtained from PQQs and alanine
H3) (Japanese Patent Application No. 1-327347), PQQ and gluta
2-Carboxyethyl OPQ (R =
CH 2CH2COOH) (Japanese Patent Application No. 1-327351)
No.), 2-carbamo obtained from PQQs and glutamine
Ilethyl OPQ (R = CH2CH2CONH2) (Special
(Heihei 327348), from PQQs and methionine
The resulting 2-methylthioethyl OPQ (R = CH2CH
2SCH3) (Japanese Patent Application No. 1-32749), PQQ
Benzyl OPQ obtained from phenylalanine
1-327350), obtained from PQQs and tyrosine
4-hydroxyphenylmethyl OPQ (Japanese Patent Application No. 2-1
07354), obtained from PQQs and aspartic acid
1-carboxymethyl OPQ (R = CH2COO
H), 1-carbamo obtained from PQQ and asparagine
Ilmethyl OPQ (R = CH2CONH2), PQQ
1- (4-Imidaryl) me obtained from and histidine
4-amino obtained from chill OPQ, PQQs and lysine
Butyl OPQ (R = (CH2)FourNH2), With PQQ
3-guanidinopropyl OP obtained from arginine
1-mercapto obtained from Q, PQQs and cysteine
Methyl OPQ (R = CH2SH) etc. Also,
The salts of OPQs are alkali metal salts and alkalis, respectively.
Earth metal salts, ammonium salts and substituted ammonium salts
The typical examples are sodium salt and potassium.
Umium salt, magnesium salt, calcium salt, ammonium
Salt, trimethylammonium salt, triethylammoniu
Rum salts, triethanol ammonium salts, etc.

【0009】また式1で示される本発明におけるOPQ
類のエステル体において、R1 、R 2 、R3 は、同一で
も異なってもよく、水素原子、アルキル基、アルケニル
基あるいはベンジル基であり、モノエステル、ジエステ
ルあるいはトリエステルがある。これらのOPQ類のエ
ステル体は、OPQ類またはその塩とアルコール類を常
法により反応することにより容易に製造することが可能
であり、アルキル基としては、メチル、エチル基などが
アルケニル基としてはアリル基などがある。又、PQQ
またはPQQ塩とアルコール類を常法により反応させ、
PQQ類のエステル体を得、その後に各種のアミノ酸あ
るいはメチルアミンと反応させることにより、目的とす
るOPQ類のエステル体を得る事も可能である。
Further, the OPQ in the present invention represented by the formula 1
In the ester form of R1, R 2, R3Are the same
May also be different, hydrogen atom, alkyl group, alkenyl
Group or benzyl group, monoester, diester
There are le or triester. Of these OPQs
Steroids usually contain OPQs or their salts and alcohols.
Can be easily produced by reacting according to the method
And examples of alkyl groups include methyl and ethyl groups.
Examples of the alkenyl group include an allyl group. Also, PQQ
Alternatively, the PQQ salt and alcohols are reacted by a conventional method,
After obtaining the ester form of PQQs, various amino acid
By reacting with ruthenium or methylamine.
It is also possible to obtain an ester form of OPQ.

【0010】[0010]

【実施例】以下に、本発明に係わるOPQ類およびその
エステル体の動物細胞の増殖促進効果を示す実施例を示
すが、本発明は、これらの実施例に限定されるものでは
ない。
[Examples] Examples are shown below showing the effect of OPQs and their esters on the growth of animal cells according to the present invention, but the present invention is not limited to these examples.

【0011】実施例1 ヒトの皮下組織由来のHFS−1線維芽細胞を10%の
牛の胎児の血清、100 unit/mLのストレプト
マイシンを添加したDulbeccoの改変Eagle
培地(DMEM培地)を用いてCO2 インキュベーター
(37℃、5%CO2 −95%空気の雰囲気下)で培養
した。この細胞をHanks液で洗浄し、血清を含まな
いDMEM培地に4×105 cell/mLになるよう
に懸濁させ平底96穴マイクロプレートに入れ、37
℃、5%CO2 −95%空気の雰囲気下で培養を行っ
た。培養開始24時間後に各培養液に、OPQをそれぞ
れ無添加、0.01、0.1、1.0、10、100あ
るいは500μg/mL添加し、さらに培養を続行し
た。培養開始後48時間後に 3H−チミジンを1.0μ
Ci/mLになるように加えさらに3時間後培養したの
ち、50%トリクロロ酢酸溶液を添加し増殖を停止した
後、細胞を洗浄し、細胞を25M NaOHで可溶化し
た後、細胞液中の 3Hを液体シンチレーションカウンタ
ーで測定した。また、同時に細胞液中の蛋白質含量を測
定した。
Example 1 HFS-1 fibroblasts derived from human subcutaneous tissue were supplemented with 10% fetal bovine serum and 100 units / mL streptomycin to prepare a modified Dulbecco Eagle.
Medium (DMEM medium) CO 2 incubator (37 ° C., under an atmosphere of 5% CO 2 -95% air) using cultured in. The cells were washed with Hanks solution, suspended in serum-free DMEM medium at 4 × 10 5 cells / mL, and placed in a flat-bottom 96-well microplate.
Culturing was performed in an atmosphere of 5 ° C, 5% CO 2 -95% air. Twenty-four hours after the start of culture, OPQ was not added to each culture medium, 0.01, 0.1, 1.0, 10, 100 or 500 μg / mL was added, and the culture was further continued. 48 hours after the start of culture, 3 H-thymidine was added to 1.0 μm.
After culturing was further added after 3 hours so that the ci / mL, after stopping the addition of 50% trichloroacetic acid solution growth, cells were washed and solubilized the cells in 25M NaOH, 3 cell fluid H was measured with a liquid scintillation counter. At the same time, the protein content in the cell fluid was measured.

【0012】結果を第1表に示す。表中の数値は6つの
同一条件での培養における1μg蛋白質当りの 3Hの取
り込み量(dpm)の平均値である。また、Hanks
液およびDMEM培地の調製法を以下に示す。Hanks液 Hanks液(日水製薬製) 475mL 2% ラクトアルブミン 25mL 7.5% NaHCO3 1.52mL 各々の液を121℃ 15分間殺菌し、使用前に無菌的
に混合する。 DMEM培地 Dulbeccoの改変Eagle培地(日水製薬製) 261mL Fetal Bovium Serum 30mL 5×10-3M 2−メルカプトエタノール溶液 3mL ペニシリン(100unit/mL) ストレプトマイシン(100unit/mL)混合液 3mL 200mM L−グルタミン溶液 3mL Fetal Bovium Serum以外は、フィル
ター濾過し、使用時に無菌的に混合する。
The results are shown in Table 1. The numerical values in the table are average values of the amount of 3 H incorporated (dpm) per 1 μg protein in the culture under the same six conditions. Also, Hanks
The method for preparing the liquid and DMEM medium is shown below. Hanks solution Hanks solution (Nissui Pharmaceutical) 475 mL 2% lactalbumin 25 mL 7.5% NaHCO 3 1.52 mL Each solution is sterilized at 121 ° C. for 15 minutes and mixed aseptically before use. DMEM medium Modified Eagle medium of Dulbecco (manufactured by Nissui Pharmaceutical Co., Ltd.) 261 mL Fetal Bovium Serum 30 mL 5 × 10 −3 M 2-mercaptoethanol solution 3 mL Penicillin (100 unit / mL) Streptomycin (100 unit / mL) mixed solution 3 mL 200 mM L-glutamine Except for 3 mL Fetal Bovium Serum, filter and mix aseptically at the time of use.

【0013】[0013]

【表1】 第1表 OPQ添加量 3Hカウント/μg蛋白質 相対活性(μg/mL) (×103 ,dpm) (%) 無添加 7.07 100 0.01 7.48 106 0.1 9.56 135 1.0 9.10 129 10 9.73 138 100 11.70 165 500 9.57 135 TABLE 1 Table 1 OPQ amount 3 H counts / [mu] g protein relative activity (μg / mL) (× 10 3, dpm) (%) No addition 7.07 100 0.01 7.48 106 0.1 9 .56 135 1.0 9.10 129 10 9.73 138 100 11.70 165 500 9.57 135

【0014】[0014]

【発明の効果】本発明の動物細胞の増殖促進剤を使用す
ることにより動物細胞の培養において細胞の増殖を効果
的に促進するとともに該細胞の有用産物の生産効率を高
めることができる。特に、本発明のOPQ類は、安定な
低分子物質であるので、従来の天然物やその抽出物に比
較して培養後の目的物質の単離精製操作が容易であり、
その実用的価値は極めて大きい。
INDUSTRIAL APPLICABILITY By using the animal cell growth promoter of the present invention, it is possible to effectively promote cell growth in animal cell culture and increase the production efficiency of useful cells. In particular, since the OPQs of the present invention are stable low molecular weight substances, the isolation and purification operation of the target substance after culturing is easy as compared with conventional natural products and their extracts,
Its practical value is extremely large.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】式1で示されるオキサゾピロロキノリン類
および/またはそのエステル体から成る動物細胞の増殖
促進剤 【化1】
1. An animal cell growth promoter comprising an oxazopyrroloquinoline represented by the formula 1 and / or an ester thereof.
【請求項2】動物細胞を培養するに際し、培地に式1で
示されるオキサゾピロロキノリン類および/またはその
エステル体を添加して該細胞の増殖を促進させ、該細胞
由来の有用産物の生産効率を高める方法 【化2】
2. When culturing an animal cell, the oxazopyrroloquinoline of formula 1 and / or its ester form is added to the medium to promote the growth of the cell and produce a useful product derived from the cell. Method to increase efficiency
JP3300972A 1991-11-18 1991-11-18 Cell proliferation promoting agent and promoting method Pending JPH05184357A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3300972A JPH05184357A (en) 1991-11-18 1991-11-18 Cell proliferation promoting agent and promoting method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3300972A JPH05184357A (en) 1991-11-18 1991-11-18 Cell proliferation promoting agent and promoting method

Publications (1)

Publication Number Publication Date
JPH05184357A true JPH05184357A (en) 1993-07-27

Family

ID=17891296

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3300972A Pending JPH05184357A (en) 1991-11-18 1991-11-18 Cell proliferation promoting agent and promoting method

Country Status (1)

Country Link
JP (1) JPH05184357A (en)

Similar Documents

Publication Publication Date Title
KR100704814B1 (en) Cyclic Boroproline Compounds
FR2609289A1 (en) NOVEL COMPOUNDS WITH ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
EP0073143B1 (en) Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
HUP0204034A2 (en) Stable salts of novel derivatives of 3,3-diphenylpropylamines
ZA200102170B (en) Antiviral purine derivatives.
ATE94547T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A TETRAHYDROPYRROL COMPOUND AS THE ACTIVE INGREDIENT AND PROCESS FOR THE MANUFACTURE OF SUCH TETRAPYRROL COMPOUND.
RU2008126305A (en) NEW PEPTID
ZA200107320B (en) Cyclic tetrapeptide derivatives and use thereof as drugs.
US6194380B1 (en) Agents for promoting bone formation
RU2009103623A (en) DERIVATIVES OF THEANINE, THEIR APPLICATION AND METHODS FOR PRODUCING THEM
EA200401108A1 (en) SALT TOLTERODINE
FI93949B (en) Process for the preparation of novel therapeutically useful salt compounds
MX9800704A (en) Esters and amides as pla2 inhibitors.
JPH05184357A (en) Cell proliferation promoting agent and promoting method
RU99103681A (en) AMIDES OF ALPHA-AMINO ACIDS, THEIR PRODUCTION AND THERAPEUTIC USE
JP4587955B2 (en) Novel molecules for developing therapeutic agents for osteoporosis
WO2001018031A3 (en) Peptides and pharmaceutical compositions comprising same
RU2004126614A (en) FINYLPYRIMIDINAMINES AS IMMUNOGLOBULIN E INHIBITORS
JP3122458B2 (en) Method for producing peptide
CN1118601A (en) Inhibitors of herpes viral ribonucleotide reductase
ATE105300T1 (en) PEPTIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
JP5560248B2 (en) Dipeptide derivative and method for producing the same
JP2868560B2 (en) Purine derivatives with pharmaceutical action
JP2598726B2 (en) Animal cell culture additives
JP4972348B2 (en) Dipeptide derivative and method for producing the same